294646-77-8
Chemical Structure
(R)-CR8
Synonym(s): CR8, (R)-Isomer
- CAS No.: 294646-77-8
- Formula:C24H29N7O
- Molecular Weight:431.53
IUPAC Name: (R)-2-((9-isopropyl-6-((4-(pyridin-2-yl)benzyl)amino)-9H-purin-2-yl)amino)butan-1-ol
InChIKey: HOCBJBNQIQQQGT-LJQANCHMSA-N
SMILES: CC[C@@H](NC1=NC(NCC2=CC=C(C3=NC=CC=C3)C=C2)=C4N=CN(C(C)C)C4=N1)CO
Biological Activity: (R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect[1][2]. (R)-CR8 acts as a molecular glue degrader that depletes cyclin K[3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-CR8 | 99.52% | (R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect. (R)-CR8 acts as a molecular glue degrader that depletes cyclin K. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-112371(S)-CR8 -
Similarity Score 0.97
HY-18340A(R)-CR8 trihydrochloride -
Similarity Score 0.77
HY-112403(S)-Roscovitine -
Similarity Score 0.77
HY-30237(R)-Roscovitine -
Similarity Score 0.77
HY-50892(Rac)-Roscovitine -
Similarity Score 0.76
HY-10380(R)-DRF053 -
Similarity Score 0.75
HY-103383(R)-DRF053 dihydrochloride -
Similarity Score 0.73
HY-112450Olomoucine II -
Similarity Score 0.67
HY-41076Ca2+ channel agonist 1 -
Explore the MedChemAI to find more analogs
References
- [1]. Bettayeb K, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. [Content Brief]
- [2]. Kabadi SV, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13. [Content Brief]
- [3]. Słabicki M, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K [published online ahead of print, 2020 Jun 3]. Nature. 2020;10.1038/s41586-020-2374-x. [Content Brief]
